首页> 外文会议>Ganoderma: Genetics, Chemistry, Pharmacology and Therapeutics >Genomic Study on Ganoderma lucidum and Development of Ganoderma Metabolites for Cancer Adjuvant Therapy
【24h】

Genomic Study on Ganoderma lucidum and Development of Ganoderma Metabolites for Cancer Adjuvant Therapy

机译:灵芝的基因组研究和用于癌症辅助治疗的灵芝代谢产物的发展

获取原文
获取原文并翻译 | 示例

摘要

Ganoderma lucidum and the related fungal species have been used in Chinese medicine and as a health food for years. These fungi exhibit a very broad spectrum of biological activities and pharmacological functions. Recently, researchers from the Veterans General Hospital-Taipei, National Yang-Ming University, National Taiwan University, and National Health Research Institutes have formed a Ganoderma consortium and completed the whole-genome sequencing (~5X) of G. lucidum by using a shotgun method. Bioinformatic study, particularly on the genes and gene cluster that are responsible for the biosynthesis of immuno-modulatory polysaccharides in G. lucidum, is currently underway. We have also elucidated the potential of Ganoderma as an adjuvant therapy for human hepatocellular carcinoma. The aim is to differentiate between hepatocytes and hepatoma cells in response to apoptosis induction by inhibiting the multiple mevalonate-demanding pathways. Human hepatoma cells (HepG2 and Hep3B) were chosen as the cellular models. Lovastatin, a lipophilic and liver-specific HMG-CoA reductase inhibitor, was used to reduce cellular mevalonate pool. The sensitivity of HepG2 cells to lovastatininduced apoptosis was similar to that of the isolated hepatocytes. Hep3B cells were more sensitive to mevalonate-deprivation. The advantage of combination treatment by using lovastatin and Ganoderma to induce apoptosis in Hep3B cells was demonstrated. An oxygenated triterpene-rich fraction of Ganoderma effectively induced apoptosis in mevalonate-deprived hepatoma cells. Reduction of cellular mevalonate pool to a stage that cholesterol synthesis was suppressed and cell growth was arrested greatly enhanced the sensitivity of hepatoma cells to a second anticancer agent including Ganoderma. Animal study by using nude mice inoculated with human hepatoma cells (Hep3B/T2) demonstrated that combination treatment of lovastatin and Ganoderma was more effective to reduce tumor growth. Microarray technique also allowed us to look into the gene expression profiles affected by this medicinal fungus. The potential of Ganoderma as an agent for cancer adjuvant therapy will be discussed.
机译:灵芝和相关的真菌种类已被用于中药和作为健康食品多年。这些真菌表现出非常广泛的生物学活性和药理功能。最近,由台北荣民总医院,国立阳明大学,国立台湾大学和国立卫生研究院的研究人员组成了一个灵芝联盟,并用sort弹枪完成了灵芝的全基因组测序(〜5X)。方法。目前正在进行生物信息学研究,特别是有关负责灵芝中免疫调节多糖生物合成的基因和基因簇的研究。我们还阐明了灵芝作为人类肝细胞癌辅助疗法的潜力。目的是通过抑制多种要求甲羟戊酸的途径来区分对凋亡诱导的肝细胞和肝癌细胞。选择人肝癌细胞(HepG2和Hep3B)作为细胞模型。洛伐他汀是一种亲脂性和肝脏特异性HMG-CoA还原酶抑制剂,用于减少细胞的甲羟戊酸池。 HepG2细胞对洛伐他汀诱导的细胞凋亡的敏感性与分离的肝细胞相似。 Hep3B细胞对甲羟戊酸剥夺更为敏感。证明了使用洛伐他汀和灵芝联合治疗可诱导Hep3B细胞凋亡的优势。富含氧化三萜的灵芝级分有效诱导了甲羟戊酸缺乏型肝癌细胞的凋亡。将细胞甲羟戊酸池减少至抑制胆固醇合成和阻止细胞生长的阶段,大大增强了肝癌细胞对包括灵芝在内的第二种抗癌药的敏感性。通过使用接种人肝癌细胞(Hep3B / T2)的裸鼠进行的动物研究表明,洛伐他汀和灵芝的联合治疗更有效地减少了肿瘤的生长。微阵列技术还使我们能够研究受此药用真菌影响的基因表达谱。将讨论灵芝作为癌症辅助治疗剂的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号